Pacific Biosciences Down 9% as FTC Challenges Sale to Illumina
December 17 2019 - 5:32PM
Dow Jones News
By Josh Beckerman
Pacific Biosciences of California Inc. (PACB) shares fell 9%
after hours to $4.85 as the Federal Trade Commission said it is
challenging the company's $1.2 billion sale to Illumina Inc.
(ILMN).
The deal was disclosed in November 2018. In January, Pacific
Biosciences said the FTC requested additional information on the
transaction.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
December 17, 2019 17:17 ET (22:17 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2024 to May 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From May 2023 to May 2024
